Granules India Ltd gets 3 observations from USFDA for Gagillapur facility

Granules India Ltd'a Gagillapur facility located at Hyderabad, Telangana, India has completed the US FDA's Pre-Approval Inspection (PAI) from 9th January 2023 to 13th January 2023 with 3(three) observations and the Company will respond to these observations within the stipulated time period.

Gagillapur facility manufactures Finished Dosages (FDs) and Pharmaceutical Formulation Intermediates (PFIs).

Shares of Granules India Limited was last trading in BSE at Rs. 318.00 as compared to the previous close of Rs. 318.15. The total number of shares traded during the day was 67901 in over 2176 trades.

The stock hit an intraday high of Rs. 322.85 and intraday low of 312.65. The net turnover during the day was Rs. 21500336.00.

Source : Equity Bulls

Keywords

GranulesIndia INE101D01020 3Observations USFDA GagillapurFacility PreApprovalInspection